Advertisement

Case Report of Pathological Complete Remission with FLEP Therapy

  • Shigekazu Ohyama
  • Osamu Komatsu
  • Toshifusa Nakajima
  • Keiichiro Ohta
  • Takashi Takahashi
  • Akio Yanagisawa

Abstract

Since 1989 at the Cancer Institute Hospital, Tokyo, we have attempted to treat patients with advanced unresectable gastric cancer with a four-drug combination chemotherapy regimen delivered systemically and regionally, followed by radical gastrectomy [1]. We report here a new case of pathological complete remission (pCR) of the primary lesion not included in our previous report. This is the first pCR case of our series.

Keywords

Gastric Cancer Advanced Gastric Cancer Paraaortic Node Inguinal Lymph Node Dissection Cancer Institute Hospital 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nakajima T, Ohta K, Ishihara S, Oyama S, Nishi M, Ohashi Y, Yanagisa (1997) Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol 4:203–208PubMedCrossRefGoogle Scholar
  2. 2.
    Donadio M, Bonardi G, Iberti V, Bertetto O, Camino F, Iskra L, Mossetti C, Calciati A (1989) The role of induction chemotherapy in inoperable ovarian cancer. Tumor 75:609–615Google Scholar
  3. 3.
    Hong WK, Schaefer S, Issell B, Cummings C, Luedke D, Bromer R, Fofonoff S, Daoust J, Shapshay S, Welch J, Levin E, Vincent M, Vaughan C, Strong S (1981) Adjuvant chemotherapy with cis-platinum and bleomycin infusion prior to definitive treatment for advanced stage III and IV squamous cell head and neck carcinoma. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer, vol III. Grune & Stratton, Orlando, FL, pp 153–160Google Scholar
  4. 4.
    Kremer B, Henne-Bruns D, Weh HJ, Effenberger T (1989) Advanced gastric cancer: a new combined surgical and oncological approach. J Hepatogastroenterol 36:23–26Google Scholar
  5. 5.
    Anderson H, Scarffe JH, Ranson M, Kamthan AG, Dougal M, Russell SA, Wilkinson MJ, Ostick DG (1991) MMAF for advanced gastric cancer. Eur J Cancer 27:1234–1238PubMedCrossRefGoogle Scholar
  6. 6.
    Konishi K, Tajiri H, Fujii T, Boku N, Ohtu A, Yoshida S, Konishi M, Hasebe T, Mukai K, Makino R (1991) An early phase II study of 5-fluorouracil combined with cisplatinum as a second line chemotherapy against metastatic gastric cancer. Jpn J Clin Oncol 21:120–124Google Scholar
  7. 7.
    Preisser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J, Meyer HJ, Buente H (1989) Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7:1310–1317Google Scholar
  8. 8.
    Kelsen D, Atig OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V, Brennan M (1992) FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric adenocarcinoma: results of a phase II trial. J Clin Oncol 10:541–548PubMedGoogle Scholar
  9. 9.
    Yonemura Y, Sawa T, Kinoshita K, Matsuki N, Fushida S, Tanaka S, Ohyama S, Takashima T, Kimura H, Kamata T, Miwa K, Miyazaki I (1993) Neoadjuvant chemotherapy for high grade advanced gastric cancer. World J Surg 17:256–262PubMedCrossRefGoogle Scholar
  10. 10.
    Deki H, Sato T (1988) An anatomic study of the peripancreatic lymphatics. Surg Radiol Anat 10:121–135PubMedCrossRefGoogle Scholar
  11. 11.
    Yonemura Y (1996) Contemporary approach toward cure of gastric cancer. Maeda Shoten, Kanazawa, Japan, pp 4–14Google Scholar

Copyright information

© Springer Japan 1999

Authors and Affiliations

  • Shigekazu Ohyama
    • 1
  • Osamu Komatsu
    • 2
  • Toshifusa Nakajima
    • 1
  • Keiichiro Ohta
    • 1
  • Takashi Takahashi
    • 1
  • Akio Yanagisawa
    • 3
  1. 1.Division of Gastrointestinal SurgeryCancer Institute HospitalTokyoJapan
  2. 2.Division of Internal MedicineFujimi-Kogen HospitalNaganoJapan
  3. 3.Division of PathologyCancer Institute HospitalTokyoJapan

Personalised recommendations